Non-invasive Tests, Portal Hypertension, and Beta-blockers: A Step Toward a Greener Environment!
- PMID: 35677511
- PMCID: PMC9168774
- DOI: 10.1016/j.jceh.2022.03.011
Non-invasive Tests, Portal Hypertension, and Beta-blockers: A Step Toward a Greener Environment!
Keywords: Baveno; HVPG; LSM, liver stiffness measurement; MELD, model for end-stage liver disease; NIT, non-invasive test; cACLD; cACLD, compensated advanced liver disease; variceal bleed.
Similar articles
-
Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta.J Hepatol. 2024 Aug;81(2):248-257. doi: 10.1016/j.jhep.2024.03.005. Epub 2024 Mar 11. J Hepatol. 2024. PMID: 38479612
-
Non-invasive tests for clinically significant portal hypertension after HCV cure.J Hepatol. 2022 Dec;77(6):1573-1585. doi: 10.1016/j.jhep.2022.08.025. Epub 2022 Sep 5. J Hepatol. 2022. PMID: 36063968
-
Application of Noninvasive Tools to Decide the Need for Beta-Blockers for Variceal Bleeding Prophylaxis in Compensated Advanced Liver Disease: A Decision Curve Analysis.J Clin Exp Hepatol. 2022 May-Jun;12(3):917-926. doi: 10.1016/j.jceh.2021.09.016. Epub 2021 Sep 25. J Clin Exp Hepatol. 2022. PMID: 35677505 Free PMC article.
-
Non-invasive tools for compensated advanced chronic liver disease and portal hypertension after Baveno VII - an update.Dig Liver Dis. 2023 Mar;55(3):326-335. doi: 10.1016/j.dld.2022.10.009. Epub 2022 Nov 8. Dig Liver Dis. 2023. PMID: 36369196 Review.
-
Evolving portal hypertension through Baveno VII recommendations.Ann Hepatol. 2024 Jan-Feb;29(1):101180. doi: 10.1016/j.aohep.2023.101180. Epub 2023 Nov 19. Ann Hepatol. 2024. PMID: 37984701 Review.
References
-
- Zarski J.P., David-Tchouda S., Trocme C., et al. Non-invasive fibrosis tests to predict complications in compensated post-hepatitis C cirrhosis. Clin Res Hepatol Gastroenterol. 2020;44:524–531. - PubMed
Publication types
LinkOut - more resources
Full Text Sources